Innovation

Atrial fibrillation: is pulsed technology the new frontier?

It is one of the most effective strategies, particularly when carried out in the early stages of the disease, when the patient’s heart is still structurally healthy

by Ernesto Diffidenti

Fibrillazione atriale: la nuova frontiera è la tecnologia ablativa

3' min read

Translated by AI
Versione italiana

3' min read

Translated by AI
Versione italiana

Atrial fibrillation is the most common cardiac arrhythmia in Italia, with around 1.1 million diagnosed patients. It affects 1–2 per cent of the general population and over 8 per cent of those aged over 65, representing one of the main causes of ischaemic stroke and A&E visits. Due to the progressive ageing of the population, it is estimated that the number of cases will almost double, reaching around 2 million by 2060.

This is a phenomenon which, on the one hand, reflects advances in medicine and improvements in quality of life, enabling people to live longer; on the other hand, it poses significant challenges in terms of care and organisation, as these patients require a continuous course of treatment and monitoring.

Loading...

Increasingly effective treatments

“Today we have increasingly effective therapeutic tools for the management of atrial fibrillation,” emphasises Patrizio Mazzone, Head of Cardiology 3 – Electrophysiology, Niguarda Hospital in Milan. “On the one hand, we have new medicines, particularly for the prevention and treatment of heart failure; on the other, we can rely on anticoagulants that we have been using for some time and which have proven highly effective in reducing the risk of thromboembolic events.” The most significant development, however, concerns technology. “In recent years,” he continues, “we have seen significant advances in the devices and materials used for transcatheter ablation, a procedure that is now one of the most effective strategies for treating atrial fibrillation, particularly when performed in the early stages of the disease, whilst the patient’s heart is still structurally healthy.”

What is Pulsed Field Ablation

Ablation has now been in use for some thirty years, “but a new form of energy, known as Pulsed Field Ablation (PFA) and based on the principle of electroporation, has recently become established. This technology is significantly changing our approach to the procedure”.

PFA uses ultra-rapid electrical pulses to selectively target and neutralise only the diseased heart cells, whilst sparing surrounding tissues such as nerves and the oesophagus. However, given the steadily rising prevalence of atrial fibrillation, access to ablation therapy is still not commensurate with the number of patients who could potentially benefit from it. This situation is due to a number of factors.

“On the one hand,” explains Alessandro Giorgetti, General Manager of Abbott’s Electrophysiology Division in Italia, “there are still cultural barriers: many patients arrive too late or continue to regard ablation as a last-resort option. On the other hand, there are organisational issues linked to the capacity of centres, the availability of procedure suites and the growing pressure on electrophysiology departments. In a context where case volumes are increasing year on year, the issue of the efficiency of care pathways becomes crucial.”

It is precisely here that Pulsed Field Ablation can act as an enabler, and Abbott is present on the market with a number of innovations. “On the one hand, Volt PFA has been designed to support procedures dedicated to pulmonary vein isolation through a standardised and highly efficient workflow,” continues Giorgetti. “On the other hand, TactiFlex Duo represents a particularly interesting development because it offers clinicians the option of using both pulsed-field energy and radiofrequency via a single catheter, enabling them to tailor the treatment strategy to any patient, clinical need or anatomy.”

The value of people and their role in the operating theatre

When we talk about innovation in healthcare, we often tend to focus on technology, but it is always people who make the real difference. This is particularly true in electrophysiology, where the evolution of platforms requires professionals capable of combining advanced technical skills with strong interpersonal skills. A background in science and bioengineering is, of course, essential, but work in the operating theatre takes place in high-pressure environments characterised by rapid decision-making and a highly multidisciplinary approach. “Our specialists,” emphasises Giorgetti, “must understand how complex systems work, interpret data in real time and support the use of highly sophisticated technologies. This is why I believe that soft skills have become just as important as technical skills. I am thinking, first and foremost, of the ability to communicate clearly and effectively, to listen to the team’s needs, to remain clear-headed and in control under pressure, and to adapt quickly to situations that may evolve during the procedure.”

And when it comes to the future of electrophysiology, the focus is no longer on a single innovation, but on the convergence of multiple technologies capable of making procedures increasingly personalised, predictive and integrated. “Artificial Intelligence, advanced imaging, high-density mapping systems and new ablation technologies are already beginning to interact with one another,” concludes Giorgetti. “The real leap forward will come when this information can be processed in an increasingly intelligent way to support clinical decision-making.”

Copyright reserved ©
Loading...

Brand connect

Loading...

Newsletter

Notizie e approfondimenti sugli avvenimenti politici, economici e finanziari.

Iscriviti